Good ideas and conversation. No ads, no tracking. Login or Take a Tour!
The field I work in is targeted delivery of antisense oligonucleotides (microRNAs, mostly) for treatment of disease. I think this field will get a lot bigger, but that might be wishful thinking. I think you'll see "omics" becoming a dying beast. Unless, of course, the NIH leadership gets populated with a lot of those people, in which case we'll probably sink even more money into it.